



Contacts: Meg McGilley
Chief Financial Officer
(858) 480-0402

Rob Whetstone
PondelWilkinson Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference

SAN DIEGO, CA – April 25, 2008 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that David Hale, executive chairman and interim chief executive officer, will present a company update at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday May 1, 2008 at 5:00 p.m. EDT. The conference will take place at the Ritz-Carlton Hotel in Key Biscayne, Florida.

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. The U.S. Food and Drug Administration (FDA) recently notified Somaxon that it accepted the New Drug Application (NDA) for SILENOR™ for review as of March 31, 2008. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Somaxon expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by December 1, 2008.

For more information, please visit the company's web site at www.somaxon.com.

###